Peer-Reviewed Technical Note: Influence of Common Excipients on the Crystalline Modification of Freeze-Dried Mannitol - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Peer-Reviewed Technical Note: Influence of Common Excipients on the Crystalline Modification of Freeze-Dried Mannitol


Pharmaceutical Technology
Volume 3, Issue 32

Abstract

Mannitol is popular as a crystalline bulking agent in freeze-drying, but tends to form different crystalline modifications which may negatively impact storage stability. Mannitol-based pharmaceutical formulations usually contain additional formulation additives which may alter the extent of crystallization and the modification of mannitol. In this study, the impact of pure sucrose, trehalose, polysorbate 80, and citric acid as well as multi-component systems of these additives, on mannitol crystallization was investigated. Pure mannitol and 10 formulations with excipients were lyophilized using identical freeze-drying conditions. The product cakes from center and edge vials were characterized using Karl Fischer residual-moisture analysis, X-ray powder diffraction, and differential scanning calorimetry. The study revealed substantial differences in residual moisture content and significant changes in crystallinity induced by even small amounts of additives, especially in the case of sucrose.

Mannitol is the most commonly used bulking agent in freeze-drying formulation design. The benefit of using mannitol is that it crystallizes during freezing and permits drying processes at higher product temperatures, and thus with higher sublimation rates relative to purely amorphous systems (1). Mannitol, however, is known to form different crystalline modifications which compromises reproducibility of product characteristics and storage stability due to phase transformations (2, 3). The different modifications have been described extensively in the literature (4, 5). Because freeze-dried mannitol-based pharmaceuticals typically contain other excipients to fulfill the stabilization needs of the active pharmaceutical ingredient, the extent of crystallization and modification may be different than for pure mannitol (6).

This study investigates the influence of frequently used additives on the crystallization of mannitol. The additives used were: sucrose and trehalose, both widely used as lyoprotectants to stabilize proteins or peptides during drying; polysorbate 80, a surfactant frequently added to avoid surface denaturation of proteins during freezing; and citric acid, a popular buffer system (1).

Materials and methods


Figure 1
All chemicals used were analytical grade and obtained from Sigma Chemical Company (Munich, Germany). Pure mannitol and 10 mixtures with excipients were lyophilized during a single run (see Table I). Nine 10-mL vials from Lutz GmbH (Wertheim,Germany) for each formulation were filled with 3-mL solution. Total solid content of each mixture was kept constant at 50 mg/mL. Freeze-drying was performed using a laboratory scale Lyostar II freeze-dryer (FTS Systems, Stone Ridge, NY). The lyophilization cycle consisted of freezing at –40 C, annealing at –15 C for 3 h hours, and primary drying at –10 C and 100 mTorr (see Figure 1). Secondary drying was performed at 40 C for 4 h. After the freeze-drying cycle, edge and center vials of each formulation were individually characterized using X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) (7). The residual moisture (RM) for one vial of each formulation was determined by Karl Fischer analysis.

Residual moisture measurements. Residual moisture was determined by coulometric Karl-Fischer titration using a water vaporizer (Mitsubishi Chemical Company CA-06 with VA-06, Tokyo, Japan). Approximately 35–90 mg of the solid samples were transferred to the vaporizer unit where the sample was heated to 140 C. Extra dry nitrogen was used as a carrier to transfer the moisture into the measurement cell.


Table I: Binary and ternary mixtures used.
X-ray powder diffraction. A 30–50 mg sample was weighed into the XRPD sample holder, compacted in the sample block, and examined using an X'Pert MPD(Royal Philips, The Netherlands)with Cu K α radiation at 40kV/40mA and 25 C. Scans were measured in the range 2θ = 0.5–40 C with a step size of 0.02 C. The diffractograms were plotted in Microcal Origin 7.5 (Originlab, Massachussettes), and the baseline corrected for a measurement offset.

Differential scanning calorimetry. The authors used a Mettler Toledo 822 DSC with STARe SW 9.01 software (Mettler Toledo, Switzerland) for thermal analysis. Approximately 20 mg of sample was weighed into a 40 μL aluminum pan and compressed in a dry-nitrogen atmosphere. Pans were then sealed hermetically and transferred into the DSC cell. Two different methods were applied. First, all formulations were scanned with a ramp rate of 10 C/min from 0 C–180 C to reveal potential glass transitions, melting events, or recrystallization. A lower ramp rate (2.5 C/min) was used for some formulations showing inconclusive results at fast ramp rates.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here